VOOPOO
2.12.2021 10:37:10 CET | Business Wire | Press release
In November, VOOPOO announced the overseas launch of the DRAG S/X PnP-X KIT. The product carries out comprehensive technical upgrading on the basis of DRAG S/X, endows the core concept of "Chivalry" in product design, and pays tribute to the glory and virtue of knights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005381/en/
Originated from the spirit of martial arts of German in the Middle Ages, the spirit of chivalry was then embodied in soldiers of the European battlefield in the 11th century, and guards of emperors and warriors of Christ. Nowadays, chivalry is culturally continued and nobly expressed as gentleman demeanor. Despite passage of time, the only constant is the faith that knight loyally holds and eight virtues of knights flowing in their blood. After learning about this legendary medieval history and digging out the core of chivalry, VOOPOO design and R&D personnel were deeply touched. The four core propositions of " Honor", " Valor", "Justice" and "Spirituality" were included in DRAG S/X PnP-X KIT product for consumers to discover. Every vaping is a fusion of VOOPOO and the connotation of the knight, and every piece of cloud is a spiritual portrait of the knight who rushes to the battlefield heroically.
DRAG S/X PnP-X KIT selects five new knight colors, each of which implies a rich design language. Shield Gold--Knight Templar for Defending Justice. Knight Red--Masked Knight for Pursuit Fairness. Knight Chestnut--Dragon Knight for Defending Glory .Eagle Black--Black Knight for Brave and Fearless. Knight Gray--Paladin for Spirituality.
PnP-X Pod displays knight’s spirituality. The metal materials and knob-filling on the top are upgraded, and the 510 drip tip can be replaced at any time. It is anti-leakage, more convenient, and more flexible. Radiating knight spirituality, PnP-X Pod will give you an enjoyable experience in vaping.
The knight series products bring an "Infinite Airflow System" that supports the adjustment of any airway. More than that, knight symbolizes of bravery and heroism. DRAG S/X PnP-X KIT embodies the knight’s valor spirit. It is equipped with a powerful GENE.TT chip, and adjustable power ranging from 5-60/80w. The product can be started in 0.001 second. The hardware is powerful enough that every knight can charge into the battle, with no worries.
The mission of the knight is to guard the country and territory, glory, and faith, and the beloved princess in their hearts. DRAG S/X PnP-X KIT fitted with 2500 mAh built-in battery and 18650 external battery respectively. The Type-C 5V/2A fast charging interface gives every knight full blood for them to resurrect in an instant. To guard the DRAG S/X PnP-X KIT is to guard the spirit of the knight, the cultural connotation of which has been inherited and innovated for thousands of years.
DRAG S/X PnP-X KIT has been upgraded based on DARG S&DARG X. The biggest highlight is the comprehensive upgrade of the atomizer. For one thing, the PnP X Pod has upgraded the metal decorative ring with knight-style texture. For another, the knob-filling on the top, which is more convenient. Anti-leakage design is more compact, and the 510 drip tip can be replaced at any time. In short, the upgrade of DRAG S/X PnP-X KIT is comprehensive, and is worthy of buying. At the same time, a vaper who likes the appearance of knights can't miss this flagship product with "chivalry spirit." Let us pay tribute to the honor of knights together!
Positioning of DRAG S/X PnP-X KIT and DARG S/X PRO is different. DARG S/X PRO is a top-fitting product for professional vapers who want to experience higher power and bigger cloud.
Founded in 2017, VOOPOO has rapidly grown within a short period of time and is now selling worldwide. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operations. It has four flagship product series: DRAG, VINCI, ARGUS and V Series. VOOPOO has more than 3000 employees worldwide and its business covers more than 70 countries and regions in North America, Europe and Asia.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
For more information, please visit https://www.voopoo.com/ , and follow our IG , Facebook and TikTok pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005381/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom